Research synthesisModerate evidenceSmall effect4 studies · 4 beneficial · 0 neutral · 0 harmful
Across all 4 studies, silymarin (milk thistle) consistently showed beneficial small-to-moderate effects on reducing alkaline phosphatase (ALP) levels, with all 4 studies reporting statistically significant findings. The most commonly studied dose was 140–420 mg daily orally, and effects were typically observed at 6–9 weeks (median study duration 63 days). Evidence predominantly comes from clinical populations, including breast cancer patients undergoing chemotherapy and adults at risk for liver injury.
- Effective dose range: 140–420 mg/day
- Studied populations: female breast cancer patients on chemotherapy, adults on antituberculosis therapy, healthy adults
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Most studies used silymarin (standardized milk thistle extract) rather than crude thistle preparations; effects may not generalize to all thistle products. Study durations were short (6–9 weeks), so long-term efficacy and safety are not well established. Two of the four studies had small sample sizes (50 and 100 participants), limiting precision.
Generated Jul 11, 2026